vs
アボット（CLB）とMESA LABORATORIES INC（MLAB）の財務データ比較。上の社名をクリックして会社を切り替えられます
アボットの直近四半期売上が大きい（$121.8M vs $65.1M、MESA LABORATORIES INCの約1.9倍）。MESA LABORATORIES INCの純利益率が高く（5.6% vs 4.2%、差は1.4%）。MESA LABORATORIES INCの前年同期比売上増加率が高い（3.6% vs -1.4%）。MESA LABORATORIES INCの直近四半期フリーキャッシュフローが多い（$18.0M vs $517.0K）。過去8四半期でMESA LABORATORIES INCの売上複合成長率が高い（5.1% vs -3.4%）
アボットは本社を米国イリノイ州アボットパークに置く多国籍ヘルスケア企業です。診断製品、栄養関連製品、医療機器を主力事業とし、米国国外向けに医薬品も販売しており、世界的に有名なヘルスケアプロバイダーです。
メサラボラトリーズ社は、品質管理、校正、モニタリング向け専門機器及び関連サービスの開発・製造・販売を事業としています。医療、製薬、食品飲料、産業衛生、環境試験分野を中心に、世界中の顧客の規制遵守と運用安全のニーズに応えています。
CLB vs MLAB — 直接比較
損益計算書 — Q1 FY2026 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $121.8M | $65.1M |
| 純利益 | $5.1M | $3.6M |
| 粗利率 | — | 64.2% |
| 営業利益率 | 1.5% | 12.2% |
| 純利益率 | 4.2% | 5.6% |
| 売上前年比 | -1.4% | 3.6% |
| 純利益前年比 | — | 316.6% |
| EPS（希薄化後） | $0.11 | $0.65 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | $121.8M | — | ||
| Q4 25 | $138.3M | $65.1M | ||
| Q3 25 | $134.5M | $60.7M | ||
| Q2 25 | $130.2M | $59.5M | ||
| Q1 25 | $123.6M | $62.1M | ||
| Q4 24 | $129.2M | $62.8M | ||
| Q3 24 | $134.4M | $57.8M | ||
| Q2 24 | $130.6M | $58.2M |
| Q1 26 | $5.1M | — | ||
| Q4 25 | $4.9M | $3.6M | ||
| Q3 25 | $14.2M | $2.5M | ||
| Q2 25 | $10.6M | $4.7M | ||
| Q1 25 | $-154.0K | $-7.1M | ||
| Q4 24 | $7.4M | $-1.7M | ||
| Q3 24 | $11.7M | $3.4M | ||
| Q2 24 | $9.0M | $3.4M |
| Q1 26 | — | — | ||
| Q4 25 | 20.8% | 64.2% | ||
| Q3 25 | 22.0% | 61.5% | ||
| Q2 25 | 20.3% | 62.0% | ||
| Q1 25 | 19.5% | 61.8% | ||
| Q4 24 | 17.8% | 63.3% | ||
| Q3 24 | 20.5% | 61.3% | ||
| Q2 24 | 21.2% | 64.0% |
| Q1 26 | 1.5% | — | ||
| Q4 25 | 11.5% | 12.2% | ||
| Q3 25 | 15.6% | 7.8% | ||
| Q2 25 | 11.7% | 5.1% | ||
| Q1 25 | 3.6% | 2.4% | ||
| Q4 24 | 11.0% | 9.2% | ||
| Q3 24 | 14.7% | 6.1% | ||
| Q2 24 | 12.3% | 9.6% |
| Q1 26 | 4.2% | — | ||
| Q4 25 | 3.6% | 5.6% | ||
| Q3 25 | 10.6% | 4.1% | ||
| Q2 25 | 8.2% | 8.0% | ||
| Q1 25 | -0.1% | -11.4% | ||
| Q4 24 | 5.7% | -2.7% | ||
| Q3 24 | 8.7% | 5.9% | ||
| Q2 24 | 6.9% | 5.8% |
| Q1 26 | $0.11 | — | ||
| Q4 25 | $0.11 | $0.65 | ||
| Q3 25 | $0.30 | $0.45 | ||
| Q2 25 | $0.22 | $0.85 | ||
| Q1 25 | $0.00 | $-1.30 | ||
| Q4 24 | $0.15 | $-0.31 | ||
| Q3 24 | $0.25 | $0.63 | ||
| Q2 24 | $0.19 | $0.62 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $22.8M | $29.0M |
| 総負債低いほど良い | — | $68.4M |
| 株主資本純資産 | $275.1M | $186.7M |
| 総資産 | $587.7M | $434.8M |
| 負債/資本比率低いほどレバレッジが低い | — | 0.37× |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $22.8M | — | ||
| Q4 25 | $22.7M | $29.0M | ||
| Q3 25 | $25.6M | $20.4M | ||
| Q2 25 | $31.2M | $21.3M | ||
| Q1 25 | $22.1M | $27.3M | ||
| Q4 24 | $19.2M | $27.3M | ||
| Q3 24 | $21.5M | $24.3M | ||
| Q2 24 | $17.7M | $28.5M |
| Q1 26 | — | — | ||
| Q4 25 | $110.3M | $68.4M | ||
| Q3 25 | $114.1M | $69.4M | ||
| Q2 25 | $124.6M | $70.3M | ||
| Q1 25 | $124.4M | $71.3M | ||
| Q4 24 | $126.1M | $72.2M | ||
| Q3 24 | $139.9M | $73.1M | ||
| Q2 24 | $147.6M | $74.1M |
| Q1 26 | $275.1M | — | ||
| Q4 25 | $266.0M | $186.7M | ||
| Q3 25 | $271.3M | $178.5M | ||
| Q2 25 | $261.3M | $172.5M | ||
| Q1 25 | $253.4M | $159.8M | ||
| Q4 24 | $246.6M | $155.2M | ||
| Q3 24 | $250.7M | $161.5M | ||
| Q2 24 | $240.3M | $150.7M |
| Q1 26 | $587.7M | — | ||
| Q4 25 | $584.0M | $434.8M | ||
| Q3 25 | $591.4M | $430.4M | ||
| Q2 25 | $602.1M | $435.7M | ||
| Q1 25 | $591.5M | $433.3M | ||
| Q4 24 | $585.1M | $433.3M | ||
| Q3 24 | $600.5M | $454.1M | ||
| Q2 24 | $597.8M | $440.4M |
| Q1 26 | — | — | ||
| Q4 25 | 0.41× | 0.37× | ||
| Q3 25 | 0.42× | 0.39× | ||
| Q2 25 | 0.48× | 0.41× | ||
| Q1 25 | 0.49× | 0.45× | ||
| Q4 24 | 0.51× | 0.47× | ||
| Q3 24 | 0.56× | 0.45× | ||
| Q2 24 | 0.61× | 0.49× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $4.0M | $18.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $517.0K | $18.0M |
| FCFマージンFCF / 売上 | 0.4% | 27.7% |
| 設備投資強度設備投資 / 売上 | — | 1.1% |
| キャッシュ転換率営業CF / 純利益 | 0.77× | 5.17× |
| 直近12ヶ月FCF直近4四半期 | $22.5M | $37.9M |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $4.0M | — | ||
| Q4 25 | $7.9M | $18.8M | ||
| Q3 25 | $8.5M | $8.2M | ||
| Q2 25 | $13.9M | $1.9M | ||
| Q1 25 | $6.7M | $12.7M | ||
| Q4 24 | $20.6M | $18.1M | ||
| Q3 24 | $13.1M | $5.3M | ||
| Q2 24 | $17.1M | $10.7M |
| Q1 26 | $517.0K | — | ||
| Q4 25 | $5.0M | $18.0M | ||
| Q3 25 | $6.5M | $7.1M | ||
| Q2 25 | $10.4M | $884.0K | ||
| Q1 25 | $3.9M | $11.9M | ||
| Q4 24 | $17.4M | $17.3M | ||
| Q3 24 | $10.4M | $3.5M | ||
| Q2 24 | $14.3M | $9.9M |
| Q1 26 | 0.4% | — | ||
| Q4 25 | 3.6% | 27.7% | ||
| Q3 25 | 4.8% | 11.7% | ||
| Q2 25 | 8.0% | 1.5% | ||
| Q1 25 | 3.1% | 19.2% | ||
| Q4 24 | 13.4% | 27.6% | ||
| Q3 24 | 7.7% | 6.0% | ||
| Q2 24 | 10.9% | 16.9% |
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 1.1% | ||
| Q3 25 | 1.5% | 1.8% | ||
| Q2 25 | 2.7% | 1.7% | ||
| Q1 25 | 2.3% | 1.2% | ||
| Q4 24 | 2.5% | 1.3% | ||
| Q3 24 | 2.0% | 3.1% | ||
| Q2 24 | 2.2% | 1.5% |
| Q1 26 | 0.77× | — | ||
| Q4 25 | 1.61× | 5.17× | ||
| Q3 25 | 0.60× | 3.32× | ||
| Q2 25 | 1.31× | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.78× | — | ||
| Q3 24 | 1.12× | 1.54× | ||
| Q2 24 | 1.90× | 3.17× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CLB
セグメントデータなし
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
